TCON 0.17 - MC $5 m- Cancer drug with final data readout in Q3 and potential FDA approval by next year .. more efficacy data readout expcted this month if positive this stock likely going through the roof .
Complete accrual of the ENVASARC pivotal trial this quarter and report updated response rate data shortly thereafter and before the end of the quarter.
Report final data from ENVASARC pivotal trial in the second half of 2024.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.